Companies · Biotechnology

Precision Biosciences Inc

DURHAM · Biotechnology

Diligence memoA one-page analyst read on Precision Biosciences Inc — recommendation, valuation, rhythm, risks.
$153.3M
Total raised · real
3
Rounds
0.4×
Latest step-up
Top 6%
Sector rank · raised
Series C
Latest stage · inferred · Fri Mar 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Precision Biosciences Inc looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.83× the median modeled value of Series C Biotechnology companies in 2019–2021 (120 peers) — value vs value, same stage and era.
  • Within the normal band (83% of peer median) for its niche.
Dormant
  • Last raise 7.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Precision Biosciences Inc is one of 4291 Biotechnology companies tracked from DURHAM. By capital raised it ranks among the largest (ahead of 95% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
23
Investors (latest)
2019-03-01
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries B · 2015-04-30 Raised $26M (real) Modeled valuation $1.0B (est)$26M$1.0BSeries B2015Series C · 2018-05-25 Raised $88M (real) Modeled valuation $3.6B (est)$88M$3.6BSeries C2018Series C · 2019-03-01 Raised $40M (real) Modeled valuation $1.6B (est)$40M$1.6BSeries C2019+$88M+$40MCumulative $153M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$25.6M · 2015
Series C$88.1M · 2018
Series C extension$39.5M · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$1.6B
Base estimate est.
$122.3M
Conservative case
$4.3B
Upside case
$263.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $1.0B · 2015-04-302015Series C · modeled $3.6B · 2018-05-25Series C · modeled $1.6B · 2019-03-012019
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
62%
Survival probability
46% low · 72% high
1.46×/yr
Annual markup
1.68×/yr upside case
6.0 yr
Elapsed time used
7.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
23 mo
Avg between rounds
$40.0M/yr
Capital velocity
11.2 yr
On record since
2015
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 21× above median
This company$153.3M
Sector median$7.2M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.9× of median
This company$39.5M
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 25× above median
This company$1.6B
Sector median$64.2M

Raised more than 95% of sector peers (real $). Modeled value above 93% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #76 of 120.

This companyCohort peer
$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Stem Biotech LLC · Series C Raised $100.0M · modeled $4.1B (est)Kinnate Biopharma Inc. · Series C Raised $172.5M · modeled $3.9B (est)Arcutis Biotherapeutics, Inc. · Series C Raised $94.5M · modeled $3.9B (est)DNA Research INST LLC · Series C Raised $94.5M · modeled $3.7B (est)M3 Biotechnology, Inc. · Series C Raised $107.3M · modeled $3.6B (est)Checkmate Pharmaceuticals, Inc. · Series C Raised $185.1M · modeled $3.5B (est)Black Diamond Therapeutics, Inc. · Series C Raised $146.3M · modeled $3.5B (est)Finch Therapeutics Group, Inc. · Series C Raised $179.9M · modeled $3.4B (est)Shattuck Labs, Inc. · Series C Raised $165.4M · modeled $3.4B (est)TScan Therapeutics, Inc. · Series C Raised $123.3M · modeled $3.3B (est)Edgewise Therapeutics, Inc. · Series C Raised $120.1M · modeled $3.3B (est)Miragen Therapeutics, Inc. · Series C Raised $197.8M · modeled $3.3B (est)Precision Biosciences Inc (this company) Raised $153.3M · modeled $1.6B (est)Precision Biosciences Inc
CompanyStageRaised · realValue · estvs peer med.
Stem Biotech LLCSeries C$100.0M$4.1B2.11×
Kinnate Biopharma Inc.Series C$172.5M$3.9B2.02×
Arcutis Biotherapeutics, Inc.Series C$94.5M$3.9B1.99×
DNA Research INST LLCSeries C$94.5M$3.7B1.88×
M3 Biotechnology, Inc.Series C$107.3M$3.6B1.88×
Checkmate Pharmaceuticals, Inc.Series C$185.1M$3.5B1.79×
Black Diamond Therapeutics, Inc.Series C$146.3M$3.5B1.79×
Finch Therapeutics Group, Inc.Series C$179.9M$3.4B1.78×
Shattuck Labs, Inc.Series C$165.4M$3.4B1.75×
TScan Therapeutics, Inc.Series C$123.3M$3.3B1.71×
Edgewise Therapeutics, Inc.Series C$120.1M$3.3B1.70×
Miragen Therapeutics, Inc.Series C$197.8M$3.3B1.69×
Precision Biosciences Inc this companySeries C$153.3M$1.6B0.83×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$25.6M2015-04-30$142.5M$1.0B85%
Series C$88.1M2018-05-25$587.2M$3.6B90%
Series C$39.5M2019-03-01$263.7M$1.6B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$25.6M2015-04-30
    • First recorded raise — entered as Series B.
    • 11 investors on this round.
  2. Series C$88.1M2018-05-25
    • Raised again after 37 mo — slower than the ~14 mo sector norm.
    • Round 3.4× larger than the prior — scaling up.
    • 40 investors on this round.
  3. Series C$39.5M2019-03-01
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 2.2× smaller than the prior — bridge or down round.
    • 23 investors on this round.
Intelligence
2021 ~Q1
Modeled next raise · ~23mo cadence
$39.5M
Modeled next size est.range $39.5M$63.3M
0.4×
Last step-up
$40.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
JEFF SMITH16 other2015-04
Ben Auspitz8 other2015-04
Robert Adelman4 other2015-04
MATTHEW KANE3 other2015-04
Shalini Sharp3 other2019-03
Tony Yao2 other2018-05
DEREK JANTZ1 other2015-04
Abid Ansari2018-05
TODD MELBY2015-04
Registry & provenance

Precision Biosciences Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1357874
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Checkmate Pharmaceuticals, Inc.BiotechnologySeries C$185.1M$3.5Bnetwork1 shared operator · same sector · same stage
Agenus IncBiotechnologySeries C$211.2M$1.2Bnetwork1 shared operator · same sector · same stage
Ultragenyx Pharmaceutical Inc.BiotechnologySeries C$108.8M$3.1Bnetwork1 shared operator · same sector · same stage
4D Molecular Therapeutics IncBiotechnologySeries C$108.6M$3.7Bnetwork1 shared operator · same sector · same stage
Mahzi Therapeutics Inc.BiotechnologySeries C$52.6M$1.3Bnetwork1 shared operator · same sector · same stage
Compass Therapeutics LLCBiotechnologySeries D+$132.6M$900.7Mnetwork1 shared operator · same sector
Tune Therapeutics, Inc.BiotechnologySeries D+$182.4M$3.1Bnetwork1 shared operator · same sector
ViaCyte Inc.BiotechnologySeries C$149.6M$1.7Bsame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Precise Bio, Inc.BiotechnologySeries B$198.8M96%
Precision Epigenomics IncBiotechnologySeed$739K95%
Precision Nanosystems Inc.BiotechnologySeries A$107.7M94%
Precision IBD, Inc.BiotechnologySeries C$1.8B91%
Precision Genetics, Inc.PharmaceuticalsPre-Seed$4.8M89%
Trait Biosciences Inc.BiotechnologySeries A$28.5M88%
SEngine Precision Medicine, Inc.BiotechnologySeries A$6.0M88%
Intuitive Biosciences, Inc.BiotechnologySeed$54.3M87%
Frequently asked
How much funding has Precision Biosciences Inc raised?
Precision Biosciences Inc has raised approximately $153.3M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Precision Biosciences Inc's estimated valuation?
Provath's modeled valuation for Precision Biosciences Inc is approximately $1.6B (modeled range $122.3M–$4.3B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Precision Biosciences Inc at?
Precision Biosciences Inc's latest modeled financing stage is Series C. Its most recent recorded round closed around Fri Mar 01.
What does Precision Biosciences Inc do and where is it based?
Precision Biosciences Inc operates in the Biotechnology sector, based in DURHAM.
Explore related

See where Precision Biosciences Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Precision Biosciences Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.